Lung NSCLC TL-EGFR-2201
Study #TL-EGFR-2201A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)
Description
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Sponsor: Teligene US
Principal Investigator: Dr. Brian Freeman
Interested in this trial? Email [email protected].
Back To Clinical Trials NCI Database Entry